Abstract 12248: The Beneficial Effects of Cardiac Stem Cell Therapy on Left Ventricular Function and Structure Persists for at Least One Year in Rats With Acute Myocardial Infarction
Administration of cardiac stem cells (CSCs) after acute or chronic myocardial infarction (MI) results in functional and structural LV improvement. However, no study has used a follow-up longer than few weeks. Consequently, it is unknown if the beneficial effects of CSCs persist beyond 5 weeks - a key issue for clinical translation. To assess the long-term effects of CSCs, rats underwent a 90-min coronary occlusion and reperfusion; 4 h later, they received intracoronarily vehicle or 1 million c-kit+ syngeneic CSCs, and then were followed for 1 year. Subsets of rats received a 1-month BrdU infusion at the 2nd, 6th, or 11th month. MI caused progressive LV wall thinning, LV chamber enlargement, and decreased ejection fraction in controls (Figure), all of which were attenuated or even reversed in CSC-treated rats. Conductance pressure-volume studies corroborated this: LVEDP, dP/dt, PAMP, PRSW, and end-systolic elastance (Ees) were improved by CSCs (Figure). Morphometric analysis showed that CSC-treated rats (n=14) had shorter LV length (13.0±0.5 vs. 15.1±0.4 mm, P<0.01), smaller scars (11.8±1.9 vs. 16.2±1.1% of total LV area, P<0.05), and more viable myocardium (66.1±4.4 vs. 54.7±2.5% of infarcted region, P<0.05). CSC treatment also increased BrdU+/α-sarc+ cells at the 2nd (467±127 in control vs. 959±92/10K nuclei in CSCs, P<0.05) and 6th (297±116 vs. 659±103, P<0.05), but not at 11th month (232±44 vs. 297±116). These data demonstrate that the beneficial effects of CSCs on post-MI LV dysfunction and remodeling persist for at least 1 year after CSC administration, indicating that CSC-mediated cardiac repair is permanent. This finding strongly supports the clinical utility of CSCs.
- © 2012 by American Heart Association, Inc.